SpringWorks Therapeutics, Inc. (SWTX)
NASDAQ: SWTX · Real-Time Price · USD
40.05
+1.65 (4.30%)
Feb 5, 2025, 11:49 AM EST - Market open
SpringWorks Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for SpringWorks Therapeutics stock have an average target of 68.83, with a low estimate of 60 and a high estimate of 78. The average target predicts an increase of 71.86% from the current stock price of 40.05.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for SpringWorks Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Maintains $80 → $78 | Strong Buy | Maintains | $80 → $78 | +94.76% | Jan 8, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Initiates $60 | Buy | Initiates | $60 | +49.81% | Nov 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $76 → $74 | Strong Buy | Maintains | $76 → $74 | +84.77% | Nov 12, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $64 → $68 | Buy | Maintains | $64 → $68 | +69.79% | Sep 4, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $76 | Strong Buy | Reiterates | $76 | +89.76% | Aug 28, 2024 |
Financial Forecast
Revenue This Year
191.20M
from 5.45M
Increased by 3,410.19%
Revenue Next Year
355.74M
from 191.20M
Increased by 86.06%
EPS This Year
-3.18
from -5.15
EPS Next Year
-2.37
from -3.18
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 202.6M | 441.4M | 728.3M | |||
| Avg | 191.2M | 355.7M | 561.4M | |||
| Low | 162.4M | 304.3M | 427.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 3,618.6% | 130.9% | 104.7% | |||
| Avg | 3,410.2% | 86.1% | 57.8% | |||
| Low | 2,882.2% | 59.1% | 20.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2028 |
|---|---|---|---|---|
| High | -3.07 | -1.82 | 0.15 | |
| Avg | -3.18 | -2.37 | -1.03 | |
| Low | -3.16 | -3.25 | -2.21 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2028 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.